Catalyst Pharmaceuticals, Inc. (CPRX): Price and Financial Metrics
CPRX Price/Volume Stats
| Current price | $15.13 | 52-week high | $17.76 |
| Prev. close | $15.34 | 52-week low | $11.09 |
| Day low | $15.03 | Volume | 7,422,100 |
| Day high | $15.80 | Avg. volume | 1,502,707 |
| 50-day MA | $15.35 | Dividend yield | N/A |
| 200-day MA | $14.15 | Market Cap | 1.79B |
CPRX Stock Price Chart Interactive Chart >
Catalyst Pharmaceuticals, Inc. (CPRX) Company Bio
Catalyst Pharmaceuticals focuses on the development and commercialization of prescription drugs targeting rare neurological diseases and disorders. The company was founded in 2002 and is based in Coral Gables, Florida.
Latest CPRX News From Around the Web
Below are the latest news stories about CATALYST PHARMACEUTICALS INC that investors may wish to consider to help them evaluate CPRX as an investment opportunity.
Small Caps Are On A Tear Including Speculative BiotechsSo far 2023 is going well with our game plan -an end-of-year seasonal rally coupled with a run in speculative biotechs driven by innovation. |
Catalyst Pharmaceuticals Announces FIRDAPSE® New Drug Application Submitted in Japan by Partner DyDo PharmaCORAL GABLES, Fla., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced that its collaboration partner, DyDo Pharma, Inc. ("DyDo"), reported that it has submitted a New Drug Application (“NDA”) to Japan's Pharmaceuticals and Medical Devices Agency (“PMDA”) seeking marketing approval |
7 Undervalued Biotech Stocks That are Flying Under the Clinical RadarWith so many innovative firms skyrocketing this year, astute investors seeking compelling discounts may want to turn their attention to undervalued biotech picks. |
Why Is Catalyst (CPRX) Up 16.2% Since Last Earnings Report?Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. |
Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2024 List of America's Most Successful Small-Cap CompaniesCatalyst Ranked #4 on the ListCORAL GABLES, Fla., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX) today announced its inclusion in Forbes' esteemed list of America's Most Successful Small-Cap Companies for the year 2024. Catalyst has ranked an impressive 4th out of 100 companies on this prestigious list, which recognizes small-cap companies that have demonstrated positive sales growth over the last twelve months. "We are very honored to b |
CPRX Price Returns
| 1-mo | -8.97% |
| 3-mo | 3.91% |
| 6-mo | 20.75% |
| 1-year | -8.19% |
| 3-year | 234.00% |
| 5-year | 180.71% |
| YTD | -9.99% |
| 2023 | -9.62% |
| 2022 | 174.74% |
| 2021 | 102.69% |
| 2020 | -10.93% |
| 2019 | 95.31% |
Continue Researching CPRX
Want to do more research on Catalyst Pharmaceuticals Inc's stock and its price? Try the links below:Catalyst Pharmaceuticals Inc (CPRX) Stock Price | Nasdaq
Catalyst Pharmaceuticals Inc (CPRX) Stock Quote, History and News - Yahoo Finance
Catalyst Pharmaceuticals Inc (CPRX) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...